Metformin, cancer and glucose metabolism

Autor: Barbara Salani 1, 2, Alberto Del Rio 3, 4, Cecilia Marini 5, Gianmario Sambuceti 2, 6 3, Renzo Cordera 1, Davide Maggi 1, 2 4

Publikováno v: Endocrine-related cancer 21 (2014): R461–471. doi:10.1530/ERC-14-0284
info:cnr-pdr/source/autori:Barbara Salani 1,2, Alberto Del Rio 3,4, Cecilia Marini 5, Gianmario Sambuceti 2,6 3, Renzo Cordera 1,2, Davide Maggi 1,2 4/titolo:Metformin, cancer and glucose metabolism./doi:10.1530%2FERC-14-0284/rivista:Endocrine-related cancer/anno:2014/pagina_da:R461/pagina_a:471/intervallo_pagine:R461–471/volume:21

Metformin is the first-line treatment for type 2 diabetes. Results from several clinical studies have indicated that type 2 diabetic patients treated with metformin might have a lower cancer risk. One of the primary metabolic changes observed in mali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2daab6853fbed8126e66cbbc4eeb473c